The COOPerative Establishment for Necessary Investigation in Clinical Outcome After Stenting (COPERNICOS)
Randomized Comparison of Outcome of Stenting in Unselected Patients in Everyday Clinical Practice
The superiority of a percutaneous coronary intervention (PCI) by one stent over another in terms of clinical outcome is usually documented in large randomized controlled trials (RCT). Although generated from selected study populations these data form the basis for evidence based practice (EBP) in the entire population of patients considered for coronary intervention. An inherent limitation of this approach is that study populations differ significantly from all comers in terms of patient characteristics and prognosis undermining the foundation for extrapolation of trial results to all comers. Furthermore, other trials are based on a "one-fits-all" concept, while the benefits of an "individual-tailored" approach that might be superior, is not investigated.
The Purpose of the current study is to
- Compare clinical outcome between several CE marked drug eluting stents
- Compare clinical outcome between several CE marked bare metal stents
- Compare clinical outcome in all comers with that of the selected study population of RCT's
- Evolve methods to compare clinical outcomes between the generalized "one-fits-all" versus the individualized or "individual-tailored" stent selection approaches
The Method employed is
- All comer PCI registry - single centre
- Randomisation of all eligible patients within the registry to one of several study stent
- Quality assurance in non-randomized population within the registry by periodical alternating the institutional standard stent
- Continuous follow up of all patients included the registry by means of systematic event detection and classification by an independent safety and end point committee
- Assessment of effects on quality of life by heart and health questionnaires
Outcome Measures
Primary endpoints:
- Composite of cardiac death, acute myocardial infraction and target vessel revascularisation
- Stent thrombosis
- A specifically developed Treatment Failure Rate classification
Secondary outcome measures include each of the above, target lesion revascularisation and total death analyzed in a hierarchical fashion at 2, 3, 4 and 5 years.
Tertiary outcome measure is self reported quality of life based on health questionnaires on general health and cardiac symptoms.
Power Calculations An event rate of 20% within 5 years, a relative difference of 25% (an absolute difference of 5%), P< 5%, Power > 80% => 900 patients in each of two treatment arms.
Prespecified Analysis include
- The MACE rates between stent types
- The Stent thrombosis rates between stent types
- The Treatment failure rates between stent types
- The randomized population versus non-randomized population
- The individualized versus the generalized Population
- QOL between stent types
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
All MACE and stent thromboses are adjudicated by an independent end point and safety committee chaired by Jørgen Jeppesen known from the very same task he executed in the SORT OUT II.
Further question may be answered by the four key investigators:
Steen Carstensen, Anders Galløe, Ole Havndrup, Lars Kjøller-Hansen
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Roskilde, Dinamarca, 4000
- Roskilde County Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- to enter COPERNICOS registry for quality assessment: Each and every patient assigned to percutaneous coronary intervention will be included.
- to enter COPERNICOS randomization: If the patient fulfil the Helsinki declaration and have a Danish personal security identification number they are asked to give written informed consent to participate in the randomized study arms.
Exclusion Criteria to randomization:
- unconscious patients
- residents in other countries thereby escaping event detection
- patients unable to understand the rationale of the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Study group two
Endeavor resolute drug eluting stent
|
Biomatrix drug eluting stent
Otros nombres:
|
|
Comparador activo: Study group three
The precise selection of brand name depends on negotiations with suppliers and may change during the study period
|
Biomatrix drug eluting stent
Otros nombres:
|
|
Comparador activo: Study group four
The precise selection of brand name depends on negotiations with suppliers and may change during the study period
|
Biomatrix drug eluting stent
Otros nombres:
|
|
Comparador activo: Study group five
The precise selection of brand name depends on negotiations with suppliers and may change during the study period
|
Biomatrix drug eluting stent
Otros nombres:
|
|
Comparador activo: Study group one
The precise selection of brand name depends on negotiations with suppliers and may change during the study period
|
Biomatrix drug eluting stent
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
MACE
Periodo de tiempo: Five year
|
Major adverse cardiac events defined as a composite of cardiac death, acute myocardial infraction and target vessel revascularisation
|
Five year
|
|
Stent thromboses
Periodo de tiempo: Five year
|
Definite, propable and possible
|
Five year
|
|
Treatment failure
Periodo de tiempo: Five Years
|
A specifically developed Treatment Failure Classification
|
Five Years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Death of any cause
Periodo de tiempo: One and five years
|
Ongoing quality assurance
|
One and five years
|
|
Self reported health questionnaires on general health and cardiac specific symptoms.
Periodo de tiempo: One and five years
|
One and five years
|
|
|
Cardiac death
Periodo de tiempo: One and five years
|
One and five years
|
|
|
Myocardial infarction
Periodo de tiempo: One and five years
|
One and five years
|
|
|
Target lesion revascularisation
Periodo de tiempo: One and five years
|
One and five years
|
|
|
Target vessel revascularisation
Periodo de tiempo: One and five years
|
One and five years
|
|
|
Stent thrombosis
Periodo de tiempo: One and five years
|
One and five years
|
|
|
Treatment Failure
Periodo de tiempo: One and five years
|
One and five years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Anders M Galløe, Md.Ph.D., Zealand University Hospital
- Silla de estudio: Steen Carstensen, MD, Zealand University Hospital
- Silla de estudio: Ole Havndrup, MD, Zealand University Hospital
- Silla de estudio: Lars Kjøller-Hansen, MD, Zealand University Hospital
- Director de estudio: Gunnar VH Jensen, MD, Zealand University Hospital
- Director de estudio: Jørgen Jeppesen, MD, Glostrup University Hospital, Copenhagen
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- COPERNICOS
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .